Media coverage about Novartis AG (NYSE:NVS) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novartis AG earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.569654043638 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news headlines that may have effected Accern’s scoring:

A number of equities research analysts have recently issued reports on NVS shares. UBS AG reiterated a “neutral” rating on shares of Novartis AG in a research note on Wednesday, May 24th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research note on Friday, June 2nd. Morgan Stanley reiterated a “sell” rating on shares of Novartis AG in a research note on Tuesday, June 6th. TheStreet upgraded Novartis AG from a “c+” rating to a “b” rating in a research note on Friday, June 2nd. Finally, Barclays PLC upgraded Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Thursday, June 22nd. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $83.56.

Shares of Novartis AG (NYSE:NVS) traded down 0.55% during midday trading on Monday, reaching $85.11. The company’s stock had a trading volume of 860,436 shares. The stock’s 50-day moving average is $84.28 and its 200 day moving average is $80.42. Novartis AG has a 12 month low of $66.93 and a 12 month high of $86.90. The stock has a market capitalization of $199.40 billion, a P/E ratio of 31.07 and a beta of 0.74.

Novartis AG (NYSE:NVS) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.06. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The company had revenue of $12.24 billion for the quarter, compared to analyst estimates of $12.20 billion. During the same period in the prior year, the company posted $1.23 EPS. The company’s revenue was down 1.8% compared to the same quarter last year. On average, analysts expect that Novartis AG will post $4.75 earnings per share for the current fiscal year.

In related news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the stock in a transaction dated Wednesday, July 5th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.01% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/18/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-novartis-ag-nvs-share-price.html.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Insider Buying and Selling by Quarter for Novartis AG (NYSE:NVS)

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.